Following FDA nod, Ferring plans launch for needle-free drug-delivery system

Ferring Pharmaceuticals said last week that the FDA approved its injectable somatropin product for four additional pediatric indications: idiopathic short stature, short stature associated with Turner syndrome, short stature born small for gestational age with no catch-up growth by 2 – 4 years and growth failure in short stature homeobox-containing gene deficiency.
In connection with the new approvals, Ferring plans to launch a needle-free drug-delivery system for its somatropin product in September this year.
Get the full story at our sister site, Drug Delivery Business News.
The post Following FDA nod, Ferring plans launch for needle-free drug-delivery system appeared first on MassDevice.

Source: Mass Device - July 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pediatrics Pharmaceuticals Regulatory/Compliance ferringpharmaceuticals Source Type: news